Prevalence and clinical implications of NRAS mutations in childhood AML: A report from the Children's Oncology Group

Leukemia

Volumn 25, Issue 6, 2011, Pages 1039-1042

  Berman, J N ^a,b   Gerbing, R B ^b   Alonzo, T A ^b,c   Ho, P A ^d,e   Miller, K ^d   Hurwitz, C ^f   Heerema, N A ^g   Hirsch, B ^h   Raimondi, S C ⁱ   Lange, B ^j   Franklin, J L ^k   Gamis, A ^l   Meshinchi, S ^b,d,e  

^a DALHOUSIE UNIVERSITY   (Canada)

^b CHILDREN S ONCOLOGY GROUP   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f Reata Pharmaceuticals Inc   (United States)

^g OHIO STATE UNIVERSITY   (United States)

^h UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

ⁱ ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^j CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^k AMGEN INC   (United States)

^l Children's Mercy Hospital and Clinics   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN; K RAS PROTEIN; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CHILDHOOD LEUKEMIA; GENE MUTATION; HUMAN; ONCOGENE N RAS; PREVALENCE; PRIORITY JOURNAL;

EID: 79958137362     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.31     Document Type: Article

References (21)

1. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326-4335. (Pubitemid 34627197)
2. Zwaan CM, Meshinchi S, Radich JP, Veerman AJ, Huismans DR, Munske L et al. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood 2003; 102: 2387-2394. (Pubitemid 37193574)
3. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352: 254-266. (Pubitemid 40110814)
4. Cazzaniga G, Dell'Oro MG, Mecucci C, Giarin E, Masetti R, Rossi V et al. Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood 2005; 106: 1419-1422. (Pubitemid 41129610)
5. Ho PA, Alonzo TA, Gerbing RB, Pollard J, Stirewalt DL, Hurwitz C et al. Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood 2009; 113: 6558-6566.
6. Janssen JW, Steenvoorden AC, Lyons J, Anger B, Bohlke JU, Bos JL et al. RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes. Proc Natl Acad Sci USA 1987; 84: 9228-9232. (Pubitemid 18055340)
7. Frohling S, Scholl C, Gilliland DG, Levine RL. Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol 2005; 23: 6285-6295. (Pubitemid 46218838)
8. Gilliland DG, Tallman MS. Focus on acute leukemias. Cancer Cell 2002; 1: 417-420. (Pubitemid 41039122)
9. Hirai H, Kobayashi Y, Mano H, Hagiwara K, Maru Y, Omine M et al. A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome. Nature 1987; 327: 430-432. (Pubitemid 17075817)
10. Hirai H, Okada M, Mizoguchi H, Mano H, Kobayashi Y, Nishida J et al. Relationship between an activated N-ras oncogene and chromosomal abnormality during leukemic progression from myelodysplastic syndrome. Blood 1988; 71: 256-258. (Pubitemid 18050423)
11. Lubbert M, Mirro Jr. J, Kitchingman G, McCormick F, Mertelsmann R, Herrmann F et al. Prevalence of N-ras mutations in children with myelodysplastic syndromes and acute myeloid leukemia. Oncogene 1992; 7: 263-268.
12. Misawa S, Horiike S, Kaneko H, Sasai Y, Ueda Y, Nakao M et al. Significance of chromosomal alterations and mutations of the N-RAS and TP53 genes in relation to leukemogenesis of acute myeloid leukemia. Leuk Res 1998; 22: 631-637. (Pubitemid 28327467)
13. Paquette RL, Landaw EM, Pierre RV, Kahan J, Lubbert M, Lazcano O et al. N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood 1993; 82: 590-599. (Pubitemid 23206126)
14. Nakagawa T, Saitoh S, Imoto S, Itoh M, Tsutsumi M, Hikiji K et al. Multiple point mutation of N-ras and K-ras oncogenes in myelodysplastic syndrome and acute myelogenous leukemia. Oncology 1992; 49: 114-122.
15. Bowen DT, Frew ME, Hills R, Gale RE, Wheatley K, Groves MJ et al. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood 2005; 106: 2113-2119. (Pubitemid 41291728)
16. Bacher U, Haferlach T, Schoch C, Kern W, Schnittger S. Implications of NRAS mutations in AML: a study of 2502 patients. Blood 2006; 107: 3847-3853. (Pubitemid 43726786)
17. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 620-625.
18. Boissel N, Leroy H, Brethon B, Philippe N, de Botton S, Auvrignon A et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 2006; 20: 965-970. (Pubitemid 43797286)
19. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909-1918. (Pubitemid 351620111)
20. Zuber J, Tchernitsa OI, Hinzmann B, Schmitz AC, Grips M, Hellriegel M et al. A genome-wide survey of RAS transformation targets. Nat Genet 2000; 24: 144-152. (Pubitemid 30094714)
21. Kim WI, Matise I, Diers MD, Largaespada DA. RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia. Blood 2009; 113: 1086-1096.